|
WO1993013101A1
(fr)
|
1991-12-27 |
1993-07-08 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
|
|
WO1998017276A1
(en)
|
1996-10-25 |
1998-04-30 |
Merck & Co., Inc. |
Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
|
|
ES2326850T3
(es)
|
1998-12-23 |
2009-10-20 |
Glaxo Group Limited |
Ensayos para ligandos de receptores nucleares.
|
|
DE60131967D1
(de)
|
2001-08-13 |
2008-01-31 |
Phenex Pharmaceuticals Ag |
Nr1h4-kern-rezeptor-bindende verbindungen
|
|
JP2006515838A
(ja)
|
2002-11-22 |
2006-06-08 |
スミスクライン ビーチャム コーポレーション |
ファルネソイドｘ受容体アゴニスト
|
|
WO2006006490A1
(ja)
|
2004-07-08 |
2006-01-19 |
Ono Pharmaceutical Co., Ltd. |
スピロ化合物
|
|
ATE526318T1
(de)
|
2005-12-19 |
2011-10-15 |
Glaxosmithkline Llc |
Farnesoid-x-rezeptor-agonisten
|
|
ES2452031T3
(es)
|
2006-02-03 |
2014-03-31 |
Eli Lilly & Company |
Compuestos y procedimientos para modular receptores FX
|
|
DK2029547T3
(da)
|
2006-05-24 |
2010-07-26 |
Lilly Co Eli |
FXR-agonister
|
|
ES2340221T3
(es)
|
2006-05-24 |
2010-05-31 |
Eli Lilly And Company |
Compuestos y procedimientos para modular fxr.
|
|
EP1894928A1
(en)
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
|
EP1894924A1
(en)
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
WO2008094556A2
(en)
|
2007-01-30 |
2008-08-07 |
Biogen Idec Ma Inc. |
Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
|
|
BRPI0812521A2
(pt)
|
2007-06-13 |
2015-06-23 |
Glaxosmithkline Llc |
Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
|
|
BRPI0812851A2
(pt)
|
2007-07-02 |
2014-09-30 |
Glaxosmithkline Llc |
Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
|
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
CA2703203C
(en)
|
2007-10-22 |
2015-12-15 |
Schering Corporation |
Bicyclic heterocycle derivatives and methods of use thereof
|
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
|
WO2010058318A1
(en)
|
2008-11-21 |
2010-05-27 |
Pfizer Inc. |
1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US8440710B2
(en)
|
2009-10-15 |
2013-05-14 |
Hoffmann-La Roche Inc. |
HSL inhibitors useful in the treatment of diabetes
|
|
JP2014500319A
(ja)
|
2010-12-20 |
2014-01-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
ファルネソイドｘ受容体を調節するための組成物および方法
|
|
WO2012087520A1
(en)
|
2010-12-20 |
2012-06-28 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
SI2861566T1
(sl)
|
2012-06-13 |
2017-03-31 |
F. Hoffmann-La Roche Ag |
Novi diazaspirocikloalkan in azaspirocikloalkan
|
|
JP6099753B2
(ja)
|
2012-10-03 |
2017-03-22 |
アドビナス セラピューティクス リミテッド |
スピロ環化合物、その組成物及びその医薬応用
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
EP3034499A1
(en)
*
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
SG11201704340VA
(en)
|
2014-12-18 |
2017-07-28 |
Novartis Ag |
Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
|
|
CN106146483A
(zh)
|
2015-04-23 |
2016-11-23 |
上海迪诺医药科技有限公司 |
杂环类法尼酯衍生物x受体调节剂
|
|
CN106946867B
(zh)
|
2016-01-06 |
2019-11-12 |
广州市恒诺康医药科技有限公司 |
Fxr受体调节剂及其制备方法和用途
|
|
CN108602811B
(zh)
|
2016-02-01 |
2021-11-16 |
轩竹生物科技有限公司 |
Fxr受体激动剂
|
|
CN107021958A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
|
SI3419624T1
(sl)
|
2016-02-22 |
2021-05-31 |
Novartis Ag |
Postopki za uporabo agonistov FXR
|
|
LT3419625T
(lt)
|
2016-02-22 |
2021-07-26 |
Novartis Ag |
Fxr agonistų panaudojimo būdai
|
|
US10080743B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US10080742B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
US10149835B2
(en)
|
2016-05-18 |
2018-12-11 |
Elmore Patent Law Group, P.C. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
AR108711A1
(es)
|
2016-06-13 |
2018-09-19 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4)
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
CN108430998B
(zh)
|
2016-09-28 |
2021-07-09 |
四川科伦博泰生物医药股份有限公司 |
氮杂双环衍生物及其制备方法和用途
|
|
CN106632294A
(zh)
|
2016-12-15 |
2017-05-10 |
宁波百纳西药业有限公司 |
一种螺环化合物及其药物用途
|